Galician genomic medicine research centre specialising in cancer risk prediction, biomarkers, and precision prevention across European and Latin American cohorts.
The Galician Public Foundation for Genomic Medicine (FPGMX) is a specialist research centre in Santiago de Compostela dedicated to translating genomic science into clinical applications, primarily in oncology. Their core work involves building and analysing large patient cohorts to identify genetic and molecular biomarkers that predict cancer risk, enabling earlier detection and more personalised prevention strategies. They combine bioinformatics, epidemiology, and clinical data integration to move from population-level genomic findings toward individualised patient management. With a track record spanning both European and Latin American cohorts, they operate at the intersection of genomic research, cancer epidemiology, and global health equity.
PanCanRisk focused on bioinformatics-driven identification of cancer susceptibility across multiple cancer types, while EULAT Eradicate GBC extends risk prediction specifically to gallbladder cancer.
PanCanRisk (EUR 558,350, coordinator) was explicitly built around personalised bioinformatics pipelines for cancer susceptibility identification and clinical management.
EULAT Eradicate GBC targets early detection biomarkers for gallbladder cancer within both European and Andean cohorts.
EULAT Eradicate GBC keywords include precision medicine and individualized prevention, signalling a shift from population-level analysis to targeted therapeutic pathways.
EULAT Eradicate GBC explicitly addresses health access disparities in Andean countries alongside European cohorts, bringing a global health dimension to their genomics work.
In their first H2020 engagement (2015–2018), FPGMX led a broad pan-cancer bioinformatics project aimed at identifying susceptibility across cancer types — a generalist genomic platform play. From 2019 onward, they sharpened their focus considerably, moving into a single high-priority cancer type (gallbladder cancer) and layering in themes of early detection, biomarkers, precision medicine, and health access in underserved populations. The trajectory is a classic narrowing-and-deepening arc: from broad cancer genomics infrastructure toward a specific disease area where they are building specialised cohort-based expertise with a global reach.
FPGMX is evolving into a niche leader in gallbladder cancer genomics with a distinctive Euro-Latin American cohort asset — making them a strong fit for future consortia targeting rare or neglected cancers in global health contexts.
FPGMX has taken both the lead and a supporting role across their two projects, suggesting they are capable of coordinating smaller consortia while also contributing specialist expertise within larger ones. Their average of 10+ unique partners per project indicates they are comfortable in mid-sized international consortia rather than bilateral agreements. The shift from coordinator to participant in their second project may reflect deliberate portfolio building — establishing domain credibility through leadership first, then joining a larger network as a recognised specialist.
FPGMX has built a network of 21 unique partners across 9 countries over just two projects, a notably broad reach for a small research centre. Their partnerships span both European institutions and Latin American partners, reflecting the bi-continental design of their gallbladder cancer research.
FPGMX is one of Spain's few publicly funded institutions dedicated exclusively to genomic medicine — not a general hospital genomics unit, but a foundation whose entire mission is translating genomics into clinical practice. Their rare combination of bioinformatics capability, cancer cohort data, and active research ties to Andean Latin America gives them a profile that almost no other European genomics centre can replicate. For consortium builders targeting cancer precision medicine with a global health dimension, they fill a highly specific and underserved niche.
